Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax, Inc. - Common Stock (NQ: NVAX )

8.190 +0.010 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
(NVAX) - Analyzing Novavax's Short Interest
Via Benzinga
Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch
A Nevada dairy worker who initially tested positive for bird flu is currently experiencing mild symptoms, including "pink eye." 
Via Benzinga
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm?
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health Organization on Monday, marking a dramatic acceleration of President Donald... 
Via Benzinga
Topics Government
Exposures Political
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains. 
Via Investor's Business Daily
Exposures COVID-19
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads
As the bird flu virus continues to spread through the United States, the Trump administration on Tuesday ordered all communications from the Centers for Disease Control and Prevention to stop. 
Via Benzinga
Topics Government
Exposures Political
Looking Into Novavax's Recent Short Interest
Via Benzinga
Why Novavax (NVAX) Stock Is Falling
Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. 
Via Benzinga
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. 
Via Benzinga
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with unknowns. 
Via Investor's Business Daily
Topics Government
Exposures Political
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing
The CDC issued a health advisory Thursday recommending that hospitalized patients who have tested positive for influenza be tested for the bird flu virus within 24 hours. 
Via Benzinga
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz
The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam. 
Via Stocktwits
Peering Into Novavax's Recent Short Interest
Via Benzinga
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
Why Novavax Stock Is Volatile This Week
Novavax shares fell 11.2% during Wednesday's session. Vaccine stocks are volatile after the first US bird flu death and a CDC report on rising respiratory illnesses. 
Via Benzinga
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies
Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind. 
Via Benzinga
Topics ETFs
Moderna, BioNTech, Novavax Surge After CDC Reports Two-Week Covid Spike
Moderna, BioNTech and Novavax stocks popped after the CDC noted a recent increase in positive Covid tests. 
Via Investor's Business Daily
Exposures COVID-19
US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally
The Louisiana Department of Health on Monday reported the first human death in the U.S. related to the H5N1 bird flu virus. The CDC is also reporting high levels of acute respiratory illnesses... 
Via Benzinga
Why Novavax (NVAX) Stock Is Rising
Novavax shares are trading higher by 12.4% during Tuesday's session. A recent CDC report highlights a sharp increase in respiratory illnesses across the United States. 
Via Benzinga
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Via Benzinga
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Dental supply maker Patterson Companies Inc announced Thursday that it is exploring strategic options, including a sale or merger, to boost shareholder value. 
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
Via The Motley Fool
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
Novavax sells Czech manufacturing facility to Novo Nordisk for $200 million, aiming to cut costs by $80 million annually and support its growth strategy. 
Via Benzinga
Is Biotech’s Bull Run Over? Examining Election Impacts
The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup. 
Via MarketBeat
Topics ETFs Government
Exposures Political
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
Pfizer, Moderna, Novavax Take A Beating After Trump Taps Kennedy To Head Up HHS
President-elect Donald Trump tapped widely known vaccine skeptic Robert F. Kennedy Jr. to lead the Department of Health and Human Services. 
Via Investor's Business Daily
Topics Government
Exposures Political
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
Trump's decision to appoint Kennedy, known for his vaccine skepticism, has sparked significant attention. 
Via Benzinga
Topics Government
Exposures Political
US Stocks Likely To Open In Red After Jerome Powell Says No Need To Be 'In A Hurry' On Rate Cuts: Tesla, TSMC And Domino's In Focus
U.S. stocks could open on a negative note on Friday after the Federal Reserve chair Jerome Powell's comments on Thursday that the economy is showing enough strength that there is no need to be "in a... 
Via Benzinga
Topics Economy
Exposures Economy Interest Rates
Trump Taps RFK Jr. For Health Secretary Role, Sends 5 Vaccine Stocks Lower
Trump may appoint Robert F. Kennedy Jr. as HHS Secretary, stirring mixed reactions. Kennedy's views on vaccines could reshape policies and affect vaccine stocks. 
Via Benzinga
Topics Government
Exposures Political
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback